Evidence map›Paper›PMID 39891781›Full record

ArticleClinical and experimental medicine2025

CircRNA circACTN4 Promotes the Progression of Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Targeting the miR-424-5p/NCAPG/Wnt Axis.

Jie Shan, Junxia Pu, Xiaohao Chen, Yeni Zhang, Jinling Li, Liumei Qin, Junhao Shi, Lv Zhou, Yibin Deng

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jie ShanThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Junxia PuThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Xiaohao ChenThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Yeni ZhangThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Jinling LiThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Liumei QinThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Junhao ShiThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Lv ZhouThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Yibin DengThe Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China. dengyb75@163.com.

Funding

Guangxi Natural Science Foundation 2018GXNSFAA281187Guangxi Science and Technology Plan Project Base and Talent Special Fund Gui Ke AD17129025National Natural Science Foundation of China 81460123
6 · The paper itself

Abstract

Growing research reveals that circular RNAs (circRNAs) play a major part in the progression and development of cancer. Here, we investigated the oncogenic function and regulatory mechanisms of the circRNA circACTN4 in hepatocellular carcinoma (HCC), particularly in the tumor epithelial-mesenchymal transition (EMT). In vitro functional assays (Cell Counting Kit 8, TUNEL, scratch wound healing, and invasion assays) of HCC cell lines, alongside in vivo analyses of subcutaneous tumors in nude model mice, were employed to assess the impact of circACTN4 on HCC proliferation. Interactions concerning circACTN4, microRNA (miR)-424-5p, and non-SMC condensing I complex subunit G (NCAPG) have been assessed deploying luciferase reporter assays and also quantitative reverse transcription PCR investigation of circACTN4 transcripts in HCC tissues. Findings indicated a high expression of circACTN4 in HCC, promoted proliferation, while inhibiting apoptosis of HCC cells, and correlated with poor prognosis. Mechanistically, circACTN4 served as a rival internal RNA for miR-424 5p, controlling NCAPG level and initiating the Wnt/β-catenin signaling routes, which in turn impacted the EMT machinery in HCC. According to our surveys, the circACTN4/miR-424 5p/NCAPG axis could be an intriguing candidate for therapy to address the treatment of HCC.

Indexed as

Carcinoma, HepatocellularEpithelial-Mesenchymal TransitionLiver NeoplasmsMicroRNAsRNA, CircularAnimalsApoptosisCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CMicroRNAsMIRN424 microrna, humanRNA, CircularcircACTN4EMTHepatocellular carcinomamiR-424-5pNCAPG

Identifiers

PMID39891781
PMCPMC11787268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.